论文部分内容阅读
乏氧细胞致敏剂Misonidazole 目前正在许多临床试用中得到评价。口服Misonidazole 后2～6小时肿瘤中的浓度为血浆浓度的12%～100%。本文通过许多人类肿瘤的一系列活检的观察,发现Misonidazole 在肿瘤中的浓度与组织学的详细结
The hypoxic cell sensitizer Misonidazole is currently being evaluated in many clinical trials. The concentration in the tumor 2 to 6 hours after oral administration of Misonidazole was 12% to 100% of the plasma concentration. Through a series of biopsy observations of many human tumors, this article found the concentration of Misonidazole in tumors and histological details.